Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrated multiomic analysis reveals comprehensive tumor heterogeneity in primary and recurrent hepatocellular carcinomas

ABSTRACT: Integrated multiomic analysis reveals comprehensive tumor heterogeneity in primary and recurrent hepatocellular carcinomas

PROVIDER: PRJNA690111 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Integrated multiomic analysis reveals comprehensive tumor heterogeneity in primary and recurrent hepatocellular carcinomas

Project description:The tumor heterogeneity between the primary and recurrent hepatocellular carcinoma (HCC) has rarely been explored. The present study aims to illustrate the heterogeneity between the primary and recurrent tumors by integrating multiomic analyses.

2023-01-06 | GSE164359 | GEO

Integrated multiomic analysis reveals comprehensive tumor heterogeneity in primary and recurrent hepatocellular carcinomas

2021-03-18 | PXD024810 |

SNP data from 125 hepatocellular carcinomas and 112 paired normal samples

Project description:SNP array data from 125 hepatocellular carcinomas were used to detect recurrent copy number alterations. 99 hepatocellular carcinomas and 86 matched normal samples were analyzed with Illumina HumanCNV370-Duo v1.0 chips. 26 hepatocellular carcinomas and 26 matched normal samples were analyzed with Illumina HumanOmniExpress BeadChip.

2012-02-27 | E-GEOD-32649 | biostudies-arrayexpress

SNP data from 126 hepatocellular adenomas and carcinomas

Project description:SNP array data from 127 hepatocellular adenomas and carcinomas were used to detect recurrent copy number alterations.

2013-12-18 | GSE43092 | GEO

SNP data from 125 hepatocellular carcinomas and 112 paired normal samples

Project description:SNP array data from 125 hepatocellular carcinomas were used to detect recurrent copy number alterations.

2012-02-27 | GSE32649 | GEO

SNP data from 126 hepatocellular adenomas and carcinomas

Project description:SNP array data from 127 hepatocellular adenomas and carcinomas were used to detect recurrent copy number alterations. 48 tumors were analyzed with Illumina HumanCNV370-Duo v1.0 chips. 79 tumors were analyzed with Illumina HumanOmniExpress BeadChip.

2013-12-18 | E-GEOD-43092 | biostudies-arrayexpress

A Genomic Portrait of Resectable Hepatocellular Carcinomas: Implications of RB1 and FGF19 Aberrations for Patient Stratification.

Project description:Whole exome sequencing and copy number analysis was performed on 231 hepatocellular carcinomas (72% with hepatitis B viral infection) that were classified as early-stage hepatocellular carcinomas, candidates for surgical resection. Recurrent mutations were validated by Sanger sequencing. Unsupervised genomic analyses identified an association between specific genetic aberrations and postoperative clinical outcomes. Recurrent somatic mutations were identified in 9 genes, including TP53, CTNNB1, AXIN1, RPS6KA3, and RB1. Recurrent homozygous deletions in FAM123A, RB1, and CDKN2A, and high-copy amplifications in MYC, RSPO2, CCND1, and FGF19 were detected. Pathway analyses of these genes revealed aberrations in the p53, Wnt, PIK3/Ras, cell cycle, and chromatin remodelling pathways. RB1 mutations were significantly associated with cancer-specific and recurrence-free survival after resection (p = 0.016 and p = 0.001, respectively). FGF19 amplifications, known to activate Wnt signalling, were mutually exclusive with CTNNB1 and AXIN1 mutations, and significantly associated with cirrhosis (p = 0.017). RB1 mutations can be used as a prognostic molecular biomarker for resectable hepatocellular carcinoma. Further study is required to investigate the potential role of FGF19 amplification in driving hepatocarcinogenesis in patients with liver cirrhosis and to investigate the potential of anti-FGF19 treatment in these patients.

2014-05-01 | GSE54504 | GEO

HOX A13 Expression in Hepatocellular Carcinomas

Project description:HOX A13 over expression represents: i) a novel molecular marker of hepatocellular carcinomas; ii) a sign of epithelial-endothelial transition accounting for tumor independent angiogenesis and lymphangiogenesis. Keywords: cancer; disease-state analysis

2008-12-01 | GSE9839 | GEO

Multiomic analyses of neoadjuvant immunotherapy treated hepatocellular carcinoma

Project description:Multiomic analyses of neoadjuvant immunotherapy treated hepatocellular carcinoma

| PRJNA1121419 | ENA

Deep Learning-based Pathway-Centric approach to characterize Recurrent Hepatocellular Carcinoma after Liver Transplantation

Project description:This study analyzed the clonal evolution at the transcriptomic level during the recurrence of hepatocellular carcinoma (HCC) after liver transplantation, utilizing a rare collection of primary and recurrent tumors.

2024-06-06 | GSE249913 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data